"Feb. 22, 2011 -- The FDA has issued a safety announcement notifying health care professionals that it has updated the pregnancy section of drug labels for the entire class of antipsychotic medications.
Antipsychotic drugs are used to "...
- Patient Information:
Details with Side Effects
MOBAN (molindone hydrochloride tablets) is indicated for the management of schizophrenia. The efficacy of MOBAN (molindone hydrochloride tablets) in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects.
DOSAGE AND ADMINISTRATION
Initial and maintenance doses of MOBAN (molindone hydrochloride tablets) should be individualized.
Initial Dosage Schedule
The usual starting dosage is 50-75 mg/day.
- Increase to 100 mg/day in 3 or 4 days.
- Based on severity of symptomatology, dosage may be titrated up or down depending on individual patient response.
- An increase to 225 mg/day may be required in patients with severe symptomatology.
Elderly and debilitated patients should be started on lower dosage.
Maintenance Dosage Schedule
- Mild-5 mg-15 mg three or four times a day.
- Moderate-10 mg-25 mg three or four times a day.
- Severe-225 mg/day may be required.
MOBAN (molindone hydrochloride) tablets are supplied in bottles of 100 tablets as follows:
5 mg Orange, round, biconvex tablet, one face debossed with “Moban (molindone hydrochloride tablets) 5”, and the other face plain. NDC 63481-072-70
10 mg Lavender, round, biconvex tablet, one face debossed with “Moban (molindone hydrochloride tablets) 10”, and the other face plain. NDC 63481-073-70
25 mg Green, round, biconvex tablet, one face debossed with “Moban (molindone hydrochloride tablets) 25”, and the other face plain with partial bisect. NDC 63481-074-70
50 mg Blue, round, biconvex tablet, one face with partial bisect and debossed with “Moban (molindone hydrochloride tablets) 50”, and the other face plain. NDC 63481-076-70
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).
Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
KEEP TIGHTLY CLOSED
Manufactured for: Endo Pharmaceuticals Inc. Chadds Ford, Pennsylvania 19317. December, 2010
Last reviewed on RxList: 1/13/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Moban Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.